Get access to all handy features included in the IVIS website
- Get unlimited access to books, proceedings and journals.
- Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
- Bookmark your favorite articles in My Library for future reading.
- Save future meetings and courses in My Calendar and My e-Learning.
- Ask authors questions and read what others have to say.
Bovine Myeloid Antimicrobial Peptide-28 (BMAP-28) mRNA Expression by Bovine Cells and Effects of Synthetic BMAP-28 on Bovine Respiratory Disease Pathogens.
Tonnelier, S.C.; Barber, C...
Get access to all handy features included in the IVIS website
- Get unlimited access to books, proceedings and journals.
- Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
- Bookmark your favorite articles in My Library for future reading.
- Save future meetings and courses in My Calendar and My e-Learning.
- Ask authors questions and read what others have to say.
Read
Objectives: Mannheimia haemolytica (MH) is the principal bacterial pathogen associated with bovine respiratory disease (BRD) in cattle. Bovine Herpes virus type 1 (BHV-1) can cause BRD by itself or it can be associated with MH or other opportunistic bacteria. Existing antimicrobials do not consistently prevent BRD due to MH, and do not have an effect against viruses; bovine antimicrobial peptides (AMP) have immune-stimulating and nonspecific antimicrobial effects that could improve BRD control. Messenger RNA (mRNA) treatment could be used to induce AMP expression in cattle, but efficacy must first be confirmed in vitro. Synthetic AMP can be generated to use as standards when characterizing mRNA-expressed AMP. We hypothesized that bovine cells can express synthetic mRNA coding for the AMP BMAP-28 and that synthetic BMAP-28 can inhibit the growth of MH and elicit antiviral effects against BHV-1 virus.
Materials & Methods: Madin-Darby bovine kidney cells were cultured and transfected with mRNA coding for BMAP-28 linked to the reporter nanoluciferase. After 4, 12, 24, and 72 hrs, relative light units (RLU) and protein concentration were measured. Results were expressed as RLU/μg of protein.
MH at 500 CFU/ml was incubated with synthetic BMAP-28 at 10 or 100 μg/ml for 0, 12, or 24 hrs, and quantitative culture was performed.
BHV-1 at 103 and 104 IU/ml were treated with synthetic BMAP-28 at 10 or 100 μg/ml and incubated at 37oC for 2 hrs. A TCID50 assay on Madin-Darby bovine kidney cells was performed for each treatment. TCID50 units were calculated after 5 days post-infection (dpi).
Results: Bovine kidney cells expressed mRNA coding for BMAP-28 with peak expression occurring at 24hs in cell lysates and supernatants. Synthetic BMAP-28 at 10μg/ml inhibited MH growth at 12 and 24hs post-treatment. Synthetic BMAP-28 at 100 μg/ml elicited antiviral effects against BHV-1.
Conclusions: Treatment of bovine cells with synthetic mRNA induces BMAP-28 expression in vitro. BMAP-28 can inhibit MH growth and BHV-1 replication. These results provide support for further research to test the mRNA-expressed product against BRD pathogens in vitro and in vivo. mRNA treatment to induce AMP expression could lead to new BRD control strategies.
Keywords: BMAP-28, mRNA, BRD, Mannheimia haemolytica, BHV-1.
Get access to all handy features included in the IVIS website
- Get unlimited access to books, proceedings and journals.
- Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
- Bookmark your favorite articles in My Library for future reading.
- Save future meetings and courses in My Calendar and My e-Learning.
- Ask authors questions and read what others have to say.
About
Affiliation of the authors at the time of publication
Department of Pathobiology and Population Medicine, College of Veterinary Medicine, Mississippi State University., Mississippi State, MS, United States;
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia, United States.
Comments (0)
Ask the author
0 comments